Gene Therapy to Target BCMA and CD19 for Blood Cancers and Systemic lupus erythematosus is under clinical development by ICell Gene Therapeutics and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gene Therapy to Target BCMA and CD19 for Blood Cancers and Systemic lupus erythematosus’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gene Therapy to Target BCMA and CD19 for Blood Cancers and Systemic lupus erythematosus overview
Gene therapy is under development for the treatment of relapsed and refractory multiple myeloma, plasmacytoid lymphoma, B-Cell acute lymphoblastic leukemia, systemic lupus erythematosus and multiple sclerosis. It is administered through intravenous route. The therapeutic candidate is being developed based on compound CAR (cCAR) technology and comprises of T cells transduced with a lentiviral vector to express BCMA and CD19 chimeric antigen receptors.
ICell Gene Therapeutics overview
iCell Gene Therapeutics (ICell Gene) is a biotechnology company. The company research and develops chimeric antigen receptor engineered cells that target multiple types of cancer with poor prognoses. It offers CARvac, T-cell targeted, compound CAR’s and universal CAR’s. ICell Gene offers orphan drug designation for five CARs in multiple myeloma, peripheral t-cell lymphoma, acute myeloid leukemia, b-acute lymphocytic leukemia and t-cell acute lymphocytic leukemia. The company creates novel CAR constructs and CAR enhancing technologies for applicability of transduced T and NK cells. It has operations in the US and China. ICell Gene is headquartered in Brookhaven, New York, the US.
For a complete picture of Gene Therapy to Target BCMA and CD19 for Blood Cancers and Systemic lupus erythematosus’s drug-specific PTSR and LoA scores, buy the report here.